This Might Be Big T's Most Controversial Call Yet

No share of Nvidia required  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

June 09, 2026 Big T recently released this controversial video… Where he said Nvidia could help fund your entire retirement… WITHOUT you having to buy a single share. Has he lost his mind? See the proof for yourself, and you’ll be the judge. He will even share his personal brokerage statement with you… Showing how he has personally made hundreds of thousands of dollars in the last 12 months with this secret. Regards, John Burke In case you missed it, here’s Big T’s Digital Asset Daily If you’ve spent the last year feeling like the only person you know who isn’t getting rich, you’re not alone. I hear the same thing constantly from friends, family, even strangers on the street when they find out what I do for work. It comes out as an almost embarrassed confession: “Everyone around me is making money on AI stocks. Am I doing something wrong?” Let me say this plainly. Sitting out a mania is one of the hardest things you will ever do as an investor. You will feel left behind. You will start to wonder whether the rules you’ve always trusted – buy quality, don’t overpay, don’t chase the crowd – have stopped working. They haven’t. And I can show you why… Because we’re about to watch the same playbook unfold again. The last time it happened, the people who refused to chase looked foolish for about a year. Then they looked like geniuses. They’ve Run This Play Before On Wednesday, I showed you why I can no longer tell my own family to simply “buy the S&P 500.” Elon Musk’s private aerospace giant, SpaceX, is widely rumored to be preparing for a massive initial public offering (IPO). And behind the scenes, the firms that run America’s biggest indexes have been loosening the rules that decide what lands in your retirement account. Nasdaq, FTSE Russell, the index behind Vanguard’s enormous total-market fund, and (by proposal) S&P have all moved to fast-track giant new listings, in some cases within days of an IPO. The machinery that’s about to force-feed SpaceX into millions of 401(k)s has done this exact thing before. It has chased the hottest, most expensive stocks on the market and dropped them straight into ordinary investors’ accounts. The blueprint is 26 years old. The last time this happened, everyday investors who bought near the peak paid the price of 15 years of sub-3% annual returns. They literally made less than 3% per year for 15 years. In late 1999, at the peak of internet mania, Yahoo was the hottest stock around. After the close on November 30, S&P announced that Yahoo would be joining the S&P 500, with the change taking effect December 7. In the single week between that announcement and the day it actually entered the index, Yahoo’s stock jumped 24%. Nothing about Yahoo’s business had changed in those seven days. The only thing that changed was that every index fund on Earth was now required to own it. And they all had to buy at once. When a stock joins an index, the funds tracking it don’t get to wait for a good price. They buy what the rulebook tells them to buy, at whatever the market is charging that day, in one great forced rush. That is precisely the price-blind demand now lining up behind SpaceX. Yahoo kept climbing into the new year, and then the bubble burst. The stock cratered along with the rest of the internet darlings… And the index funds that had been marched in at the top got to ride it all the way down as it dropped from a high of $118.75 to as low as $4.41. And it wasn’t just Yahoo. As the bubble swelled, the S&P committee waved in a whole parade of high-flyers near the very top. Names like AOL and Global Crossing, companies that would soon crater or collapse into bankruptcy. The irony is that millions of investors believe index funds protect them from bubble behavior. But at major market peaks, the index itself can become the mechanism that concentrates everyone into the exact same overheated trades. The bigger and more euphoric a company becomes, the more money passive funds are forced to pour into it, regardless of valuation. It’s why Financial Times correspondent Robin Wigglesworth recently called this dynamic “the biggest bagholder exercise of all time.” The “Chump” Who Was Right Now picture the investor who sat all of this out in 1999. For months, they looked like the village idiot. Neighbors were doubling their money in dot-coms. Co-workers were quitting their nine-to-fives to day-trade. And there sat the disciplined investor with their boring, sensible portfolio, plodding along, clearly missing the boat. Then the boat sank. The Nasdaq peaked on March 10, 2000. Over the next two and a half years it got hammered down 78%. It took 15 years for it to climb back to even. The S&P 500 lost about half its value. By 2004, more than half of public dot-com companies had failed. Amazon was a genuinely world-changing company – one of the greatest businesses ever built. The problem wasn’t the company. The problem was the price investors paid during the frenzy. Even after becoming one of the most dominant companies in modern history, Amazon’s stock still collapsed more than 90% after the dot-com peak, before it eventually recovered. Being right about the technology did not protect investors from overpaying for it. So if you feel like a chump right now for staying disciplined while everyone else piles into the hottest AI stocks, understand that in hindsight you will be the one standing on the right side of history. The careful investor of 1999 looked foolish for a little over a year. Then they spent the next decade watching the crowd claw its way out of an 80% crater. That uncomfortable, left-behind feeling you have if you’re being selective, instead of rushing into the latest AI darlings, is very often what being early to the right answer feels like. The Dot-Com Playbook Is Back If you think the dot-com era was a one-time mistake, consider that they ran this exact play again just a few years ago with Tesla. In December 2020, Tesla became the largest company ever added to the S&P 500. Index funds were forced to buy somewhere between $50 and $90 billion of it, at the top of a year in which the stock had risen roughly 700%. The shares jumped about 14% the day the addition was announced. Two years later, the index investors who’d been force-fed Tesla at around $232 a share were still underwater – sitting below what they paid – even though the broader S&P 500 had risen over the same stretch. Tesla may ultimately become one of the defining companies of this generation. That still didn’t stop index investors from overpaying for it at the height of the frenzy. Now it’s SpaceX. It has a rumored price tag near $1.8 trillion, despite posting roughly $4.9 billion in losses last year. It also has a tradeable “float” of just 4.3% of its shares. That means the vast majority of the company will remain locked up and unavailable to the public. Compare that to Microsoft, where 99% of its shares trade freely. Think of it like trying to force a firehose of water through a tiny drinking straw. You’re cramming an estimated $15-30 billion of forced, must-buy institutional demand into a tiny sliver of available stock. And yet, the index machinery is lining up to buy it on your behalf. Sitting Out the Madness Was Never Sitting Out the Profits Here’s what I need the disciplined reader to hear: Refusing to chase the herd is not the same as refusing to make money. You do not have to choose between keeping your sanity and growing your wealth. While the crowd and the index piled into the hottest, priciest names of the last cycle, the real money was made by the people who chose deliberately. Who bought early, in asymmetric setups, before the forced buyers ever showed up. That’s the whole idea behind our Asymmetric Edge publication: Find the opportunity underneath the obvious story, take a measured position while it’s still cheap and ignored, and let the crowd arrive later and pay up. The crowd will line up on June 12 to buy one of the most expensive IPOs in history. The index will shovel even more in behind them. We’re not playing that game. We’re choosing what we own – early, and on our own terms. Daily Editor Teeka Tiwari recently recorded a briefing walking through exactly this approach. You can watch it here. Remember this: The disciplined investor of 1999 never felt vindicated on the way up. They felt it on the way down, when the same people who’d called them too cautious were down 80%, and they still had their capital, intact and ready to put to work near the bottom. If you’ve been feeling early and alone lately, it’s worth remembering that’s exactly where the disciplined investor was standing in late 1999. Sitting out the madness is not about avoiding risk. It’s about refusing to overpay for it. Don't Watch the Future Happen. Own It! Houston Molnar Share The Digital Asset Daily You currently have 0 referrals. Click to Share Or copy and paste this link to others: https://tiwariresearchgroup.com/subscribe?ref=smdz7lJ2jD   Update your email preferences or unsubscribe here © 2026 Tiwari Research Group 1607 Ponce De Leon Ave San Juan, Puerto Rico 00909, Puerto Rico Terms of Service

Here’s an Early Morning Look At Why (Nasdaq: FEED) is Topping Our Watchlist Today

Any content you receive is for information purposes only. Always conduct your own research.  *Sponsored Market Crux Just Put ENvue Medical, Inc. (NASDAQ: FEED) at the Top of the Watchlist This Morning—Tuesday, June 9, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At (FEED) While It’s Still Early… June 9, 2026 Here’s an Early Morning Look At Why (Nasdaq: FEED) is Topping Our Watchlist Today Dear Reader, At Market Crux, we are constantly searching for companies showing a combination of fresh developments, expanding commercial reach, and meaningful industry validation. One name recently checked several of those boxes: ENvue Medical, Inc. (Nasdaq: FEED). The company has reported new peer-reviewed clinical results, expanded deployment within a major academic health network, and continues to build its presence across U.S. hospitals. Add in a public float of less than 6M shares and the fact that FEED is currently trending below $1 according to Barchart data, and the company quickly earned a spot near the top of our watchlist this morning—Tuesday, June 9, 2026. Keep reading to what just put FEED on our radar. Across the United States, hospitals perform more than 13M feeding tube placements every year — yet a staggering 85% of those procedures are still performed blindly, without any real-time visual guidance, forcing clinicians to wait on radiology confirmation before a single drop of nutrition can reach a patient. (FEED) built its platform specifically to fix that problem — and this week, independent peer-reviewed science confirmed that it works. A study just published in the official journal of the American Association of Critical Care Nurses showed the ENvue™ Navigation Platform saved over 350 nursing hours in year one, cut repeat imaging by 20%, and reduced hospital-acquired aspiration pneumonia by 20% across a multi-hospital health system. Those aren't projections. They are real-world, independently documented clinical outcomes. The commercial story around this name has been developing fast — and there are now even more reasons to have FEED on your radar this morning. Company Overview FEED is headquartered in Tyler, Texas, with research and development operations in Tel-Aviv and Nesher, Israel. The company operates two distinct technology platforms that together address a wide range of clinical and home-care needs. The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system that assists clinicians in placing nasoenteral feeding tubes at the bedside with real-time visual guidance. The system is FDA 510(k) cleared for adult use and is now commercially deployed across 40 U.S. hospitals, generating recurring consumable revenue as clinicians integrate it into their daily workflow. The company's second platform, the Acoustic Therapeutic Platform, includes PainShield® and UroShield® — devices utilizing proprietary low-intensity surface acoustic wave (SAW) technology designed for pain reduction, biofilm disruption, and bacterial colonization prevention in home and clinical settings. UroShield recently secured reimbursement approval in the UK, adding an international revenue channel through distributor Peak Medical. Leadership is anchored by Doron Besser, MD, Chief Executive Officer, with Marc Waldman serving as VP of Commercial — bringing over 35 years of medical device commercial leadership to the role. David Johnson serves as Chairman of the Board. The Market Potential FEED operates at the intersection of two growing sectors. The global enteral feeding devices market is valued at approximately $4.97B in 2026 and is projected to reach $8.98B by 2035, expanding at a CAGR of 6.8%. Within the U.S. alone, more than 6M patients rely on enteral feeding annually, and approximately 500,000 gastrostomy tube placements occur each year. North America commands roughly 38% of global demand, underpinned by high healthcare spending, an aging population, and rising rates of chronic disease. The clinical case for navigation-guided placement is compelling. Pulmonary misplacement — when a tube inadvertently enters the lungs — is a preventable but potentially fatal event. Blind placement also creates imaging bottlenecks as hospitals wait on radiology confirmation before feeding can begin. Real-time bedside guidance directly addresses patient safety mandates, staffing shortages, and cost pressure — simultaneously. Now, peer-reviewed data puts hard numbers behind that clinical case. Peer-Reviewed Science Now Backs the Platform On June 3, 2026, FEED announced the publication of an independent, peer-reviewed study in Critical Care Nurse — the official journal of the American Association of Critical Care Nurses — documenting outcomes from the ENvue™ Navigation Platform across a multi-hospital health system including Inova Health System. The results are specific and independently verified: Over 350 nursing hours saved in year one of deployment 20% reduction in repeat X-rays needed to confirm feeding tube placement — reducing delays in starting patient nutrition and cutting unnecessary radiation exposure 20% reduction in hospital-acquired aspiration pneumonia 67% reduction in ventilator-associated pneumonia cases A dramatic increase in bedside postpyloric feeding access — a capability previously requiring interventional radiology — with no additional clinical staffing required Potential savings of over $1.5M in hospital costs In a post-implementation survey, clinicians reported the system was easy to use, improved patient safety, and provided accurate real-time guidance — with nearly all saying they would recommend it. The study covered five hospitals with diverse intensive care units. Burn ICU Expansion Signals Growing Clinical Versatility Two days after that publication, on June 5, 2026, FEED announced that a major U.S. academic health network has expanded its use of the ENvue™ Navigation Platform into its American Burn Association-verified burn intensive care unit — marking the second deployment within the same health system. Burn ICU patients represent one of the most clinically challenging and vulnerable populations in hospital medicine. Feeding tube placement in this setting carries elevated risk, and the decision to expand an existing platform relationship into the burn ICU — rather than simply maintaining current deployments — signals a level of institutional trust that goes well beyond standard contract renewals. CEO Doron Besser, MD, addressed it directly: "We believe that this health network's decision to bring the ENvue Navigation Platform into their burn ICU speaks directly to the clinical versatility of our platform and institutional trust that we have earned with this network." The fact that this expansion occurred within a health system already using the platform — and came just days after peer-reviewed clinical results from a multi-hospital Inova deployment — suggests a pattern of deepening institutional commitment rather than one-off adoption. Commercial Momentum: The Bigger Picture Before these two most recent developments, FEED had already been building a compelling commercial foundation: On May 12, 2026, FEED announced that its ENvue™ Navigation Platform was adopted as the standardized protocol for bedside feeding tube placement across a 12-hospital integrated non-pro-fit health network in Virginia and North Carolina — a three-year renewal running through 2028. Standardized protocol status means the platform is embedded directly into clinical workflow as the method of care, driving consistent utilization across the network rather than simply being available for optional use. On May 7, 2026, FEED locked in a three-year GPO purchasing agreement renewal tied to one of the largest non-pro-fit health systems in the U.S. — encompassing more than 90 hospitals across 17 states. Any participating hospital can now move directly to adoption without navigating lengthy value analysis committee approvals. CEO Doron Besser, MD, stated the arrangement makes the platform "one clinical decision away from adoption" at any participating facility. FEED also holds two recently issued USPTO Notices of Allowance — one covering a next-generation feeding tube combining electromagnetic navigation with a distal-tip camera, and a second covering SAW technology applied to transdermal compound delivery — broadening the IP portfolio into pain management, neurology, and inflammation applications. Here’s 7 Reasons Why FEED Just Landed On Our Watchlist This Morning—Tuesday, June 9, 2026… 1. Patent Growth: FEED recently received two USPTO Notices of Allowance covering next-generation feeding tube technology and additional applications for its proprietary SAW technology, expanding its intellectual property portfolio. 2. Small Float: With fewer than 6M shares listed as available to the public, FEED’s small float could have the potential to witness big moves if demand begins to shift. 3. Hospital Expansion: FEED reported that a major U.S. academic health network expanded use of the ENvue™ Navigation Platform into its burn intensive care unit, marking a second deployment within the same health system. 4. Peer-Reviewed Results: FEED recently announced publication of an independent peer-reviewed study showing its ENvue™ Navigation Platform saved more than 350 nursing hours while reducing repeat X-rays and hospital-acquired aspiration pneumonia by 20%. 5. Protocol Status: FEED secured standardized protocol adoption across a 12-hospital non-pro-fit health network, embedding the platform directly into routine bedside feeding tube placement workflows through 2028. across 17 states, creating access to a large network of potential users. 6. Dual Platforms: FEED operates both the ENvue™ Navigation Platform and its Acoustic Therapeutic Platform, giving the company exposure to multiple clinical and home-care applications rather than relying on a single product line. 7. Broad Reach: FEED renewed a three-year GPO purchasing agreement connected to a non-pro-fit health system encompassing more than 90 hospitals. Take A Look At (FEED) While It’s Still Early… The story surrounding FEED is no longer centered on a single announcement. The company has recently reported peer-reviewed clinical outcomes, expanded within an existing academic health network, secured additional intellectual property milestones, and continued broadening its commercial footprint across the healthcare landscape. Add in a public float of less than 6M shares, and it becomes clear why FEED has moved to the top of the Market Crux watchlist heading into this morning’s session. That is why FEED is the first name and only name on our screen right now. Take a closer look at FEED before the bell rings. Sincerely, Gary Silver Managing Editor, Market Crux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. ENvue Medical, Inc. (FEED:US) previously changed their company name and symbols from NanoVibronix Inc. (NAOV:US) Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 06/08/2026 and ending on 06/09/2026 to publicly disseminate information about (FEED:US) via digital communications. Under this agreement, TD Media LLC has paid Headline Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the ninety thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (FEED:US). Please see important disclosure information here: https://marketcrux.com/disclosure/feed-Gkplh/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe Update Profile | About our service provider Sent by gary@marketcrux.net

Stocks Rebound After Losses, All Eyes On This Week's Inflation Reports

Today's Market Moves from Zacks  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Stocks Rebound After Losses, All Eyes On This Week's Inflation Reports

	Profit from the Pros By Kevin Matras Executive Vice President
	Stocks Rebound After Losses, All Eyes On This Week's Inflation Reports Stocks closed mostly higher yesterday, led by the Nasdaq with 0.86%, followed by the small-cap Russell 2000 with 0.77%. Only the Dow missed the cut, giving up -0.16%. Many AI-related stocks that got pummeled on Friday, rebounded sharply on Monday. Marvell gained 9.63%; Micron rallied 9.87%; Advanced Micro Devices was up 5.14%; Intel was up 11.19%; Sandisk was up 5.30%; and NVIDIA added 1.73%. Didn't totally erase Friday's losses. But a good chunk of them. But it does appear some long overdue profit taking was seen. Will it turn into a pullback for the major indexes? It's possible. Pullbacks are defined as a decline between -5% and -9.99%. But they are very common. And they happen on average of 3-4 times a year. Every bull market has them. And it would be perfectly normal if we got one. Especially after the spectacular rally we've seen over the last couple of months. But pullbacks are also short-lived. Since 1990, the typical pullback lasted about 28 days. And if you know pullbacks and corrections are commonplace moves, you can instead look at them as opportunities to buy rather than places to sell. Plus, the AI trade is alive and well. And aside from that, the economy is doing well. Last Friday's employment report shows the labor market is doing well. And corporate earnings are doing well. More than well. They're doing great. Q1'26 earnings season just showed the S&P 500 EPS growth rate at 23.3%. Q2'26 is forecast at 21.2%. Q3'26 is forecast at 18.4%. And Q4'26 is forecast at 20.4%. Not a stretch to expect another double-digit gain this year, to the tune of 20% or more for the S&P 500, given the double-digit growth rates for the rest of the year. Not much in the way of economic reports out yesterday. But today we'll get the NFIB Small Business Optimism Index, the International Trade in Goods and Services report, and Existing Home Sales. But the main events this week will be the upcoming inflation reports. On Wednesday we'll get the Consumer Price Index (CPI) retail inflation report, and then on Thursday, we'll get the Producer Price Index (PPI) wholesale inflation report. Inflation has been ticking higher lately. Not as much as expected. But higher nonetheless. Between that and the better-than-expected jobs gains we're seeing, the timeline has already been pushed out for the next rate cut. But the last FOMC Minutes showed some suggesting we could see a rate increase if inflation keeps rising. So all eyes will be on this week's inflation reports. And those will be the last inflation reports we'll get before next week's FOMC Announcement 6/17. In the meantime, we've got a whole rest of the week to get thru first. See you tomorrow, Kevin Matras Executive Vice President, Zacks Investment Research
	Sponsor AI Runs on Power. Power Runs on Uranium. AI demand is surging and nuclear capacity is expanding to meet it. But fuel supply hasn't kept up. And when demand runs ahead of supply, things shift. A recent IPO on the NYSE sits right inside that imbalance. See the Opportunity Forming >
	Today's Top Research New Zacks Strong Buys for June 9th Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today. Read More » OpenAI IPO 2026 Guide: Date, Expected Valuation, and How to Invest in ChatGPT Investors are now asking whether the company behind ChatGPT could become one of the biggest public offerings in history. Read More » 3 Retail Stocks to Watch After Crushing Q1 EPS Expectations: FIVE, ULTA, VSXY The retail earnings season has revealed a clear theme: companies with strong brands, differentiated customer experiences, and disciplined execution are still thriving. Read More » 2 AI Stocks Up 281% to Over 3600% That Could Be the Next NVIDIA Among the names drawing attention are AI memory stock, SNDK and AI networking chipmaker MRVL. Read More » A Few Reasons to Buy the Dip in AI & Chip ETFs A sharp AI-chip selloff has rattled markets, but strong long-term demand, easing supply constraints and still-manageable valuations may create buying opportunities. Read More »
	See Zacks' Top Stocks for Free Starting today, you can get instant access to the latest picks from our time-proven strategies which since 2000 have soared far above the market. While the S&P 500 averaged +8.1% per year, our top strategies averaged gains as high as +45.4%, +48.1% and +51.4% per year. You'll also get our free Special Report, Top 10 Stock Screening Strategies that Make Money which spells out the formulas behind these top strategies. See Stocks Free >>
	Should You Buy, Sell or Hold Oracle Stock Before Q4 Earnings? Oracle's expanding cloud portfolio, multicloud database momentum, and significant government contract wins present a compelling growth narrative. Read More » Bull of the Day: Ultra Clean Holdings (UCTT) Ultra Clean Holdings (UCTT) is emerging as one of the strongest beneficiaries of the ongoing artificial intelligence (AI)-driven semiconductor spending boom. Read More »
	More Zacks Resources Mobile App Download our app for convenient on-the-go access to even more—daily and weekly newsletters published by Zacks experts, proprietary research and tools, and Portfolio Tracker on Zacks.com.
	Zacks Members' Success Stories Visit Success Stories to hear how Zacks research, tools and portfolios help our members outperform the market.
	Get all of our market insights and much more when you connect with us.
	This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service". www.zacks.com/terms_of_service Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or U.S. investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through April 6, 2026. The performance is the equal weighted performance of a hypothetical portfolio consisting of stocks with a Zacks Rank of #1 that was rebalanced monthly from January 1988 through December 2013 and weekly from 12/31/13 through Monday's open on April 6, 2026. For each stock with a Zacks Rank #1 at the beginning of the month, the total return during the month was calculated as the % change in the price of the stock from the closing price of the prior month to the closing price of the current month plus any dividends received during the month. The monthly individual stock returns were then averaged to determine the portfolio return for the month. For each stock with a Zacks Rank #1 at the beginning of the week, the total return during the week was calculated as the % change in the price of the stock from the opening price for the week to the opening price of the next week plus any dividends received during the week. The weekly individual stock returns were then averaged to determine the portfolio return for the week. If no month-end price or week end open price was available for a stock, it was not included in the portfolio return for the month or the week. The monthly and weekly returns were compounded to arrive at the annual returns. The annualized return is the annual return that, had it been achieved in each year or portion of a year, would have compounded to create the total return over the full time period. These returns are based on the list of Zacks Rank #1 Stocks that was available to clients of Zacks as of the beginning of the month, when returns were calculated monthly, or as of the beginning of the week when returns were calculated weekly. These returns are higher than the returns an investor could achieve investing real money in a portfolio of Zacks Rank #1 stocks because the returns of the hypothetical Zacks Rank #1 portfolio exclude a number of costs, including commissions incurred for trading, the average bid ask spread, the price impact of the trading and, prior to 2013, in those months when the end of the month fell on Friday, Saturday or Sunday, the overnight return from the month end close to the open on the next trading day. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance_disclosure for information about the performance numbers displayed above. Zacks Emails If you would prefer to not receive future profit-producing emails from Zacks.com the primary purpose of which is the commercial advertisement or promotion of a commercial product or service, then please click here and confirm your request. If you have trouble with the unsubscribe link, please email support@zacks.com. Zacks Investment Research 101 N. Wacker Drive, Floor 15 Chicago, IL 60606